Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.
EP: 1.Overview of colorectal cancer and its management
EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care
EP: 3.Circulating Tumor DNA Detection Techniques
EP: 4.Describing the Value of ctDNA in Clinical Practice
EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update
EP: 6.Recent findings from BESPOKE
EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
EP: 8.Key Considerations for Selection of ctDNA Detection Methods
EP: 9.Clinical Utility of ctDNA Testing
EP: 10.Barriers to Implementing ctDNA Testing
EP: 11.ctDNA Testing in a CRC Clinical Scenario
EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
EP: 13.Interpreting and Communicating ctDNA Results
EP: 14.Addressing Gaps in ctDNA Testing
EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies
- Please discuss the clinical implications of these recent data for the utility of ctDNA-based MRD testing in CRC treatment and management
- Are any of these findings practice-changing?
- Are you routinely testing patients after surgery and after adjuvant therapy on the basis of these data?
- What are some barriers to enrollment surrounding MRD testing in CRC for ongoing adjuvant studies (like CIRCULATE)?
- Are patients wanting to escalate or de-escalate treatment?
- How are patients reacting to study testing?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
